- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04713046
Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
November 1, 2023 updated by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Phase I Clinical Trial Assessing the Safety, Feasibility and Immunologic Correlates of Allogeneic HPV-specific Cluster of Differentiation 4 (CD4)+ T Cells in Advanced HPV16-associated Malignancies
In this study, haploidentical relatives of a patient with recurrent or metastatic HPV 16-associated malignancy will be vaccinated with a therapeutic human papillomavirus (HPV) vaccine series to generate HPV-specific leukocytes.
The cancer patient with recurrent or metastatic HPV16+ cancer will then be randomized to one of two arms: 1) non-myeloablative allogeneic bone marrow transplant or 2) cluster of differentiation 8 (CD8)-depleted donor lymphocyte infusion.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tanguy Seiwert, MD
- Phone Number: 410-955-8893
- Email: tseiwert@jhmi.edu
Study Contact Backup
- Name: Adrienne Holmes, RN
- Phone Number: 410-955-9927
- Email: aholme26@jhmi.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Recruiting
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
Contact:
- Tanguy Seiwert, MD
- Phone Number: 410-955-8893
- Email: tseiwert@jhmi.edu
-
Contact:
- Adrienne Holmes, RN
- Phone Number: 410-955-9927
- Email: aholme26@jhmi.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have pathologically confirmed incurable, locally recurrent or metastatic HPV16+ HNSCC
- Male or female ≥ 18 years of age
- Have an human leukocyte antigen (HLA) partially mismatched (haploidentical) related donor. Acceptable donors include first degree relatives (parent, child, or haploidentical sibling), half-siblings, or second degree relatives (aunt, uncle, cousin, niece, nephew). A patient who has inherited a recombinant haplotype from the parents is eligible if the donor shares at least 1 HLA antigen at each of the HLA-A, HLA-B, and HLA DR isotype (HLA-DR) loci.
- Prior treatment with a platinum-containing regimen
- Patients with an FDA-approved indication to receive an anti-programmed cell death protein-1 (PD-1) or anti-programmed death-ligand1 (PD-L1) monoclonal antibody must have received at least one cycle of this therapy prior to receiving treatment on this trial
- Life expectancy ≥ 4 months at time of screening
- Measurable disease using RECIST 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been documented in such lesions
- Eastern Cooperative Oncology Group (ECOG) performance status of < 2 (see Appendix A).
Adequate organ function per the protocol, as defined below:
- Left ventricular ejection fraction > 35% (within 30 days of eligibility screening)
- Total bilirubin < 3.0 mg/dl unless from Gilbert disease
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 4 x institutional upper limit of normal
- Serum creatinine < 3.0 mg/dl
- Willing and able to provide written informed consent
Exclusion Criteria:
- Disease that is suitable for local therapy administered with curative intent
- Requires vasopressor or ventilator support
- Received antithymocyte globulin or similar anti-T-cell antibody therapy ≤ 4 weeks prior to Cycle 1 Day 1
- Diagnosis of immunodeficiency or is receiving systemic steroid therapy >10 mg/day of prednisone or equivalent, or any other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 of study treatment.
- Active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
- Active infection requiring systemic therapy
- History of (non-infectious) pneumonitis that required steroids or current pneumonitis
- Received any live vaccine for up to 30 days prior to enrollment.
- Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer not associated with HPV16.
- Pregnancy or breastfeeding: females of childbearing potential must have a negative serum pregnancy test.
- Female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception (abstinence is acceptable) for the course of the study through 120 days after the last study dose since the effects of this therapy on the developing human fetus are unknown.
- Inability to comply with study procedures
- Received chemotherapy or targeted small molecule therapy within 2 weeks of the first dose of cyclophosphamide. Subjects must have recovered (ie, grade ≤ 1 or at baseline) from adverse events (AEs) due to a previously administered agent. Subjects with grade ≤ 2 neuropathy or grade ≤ 2 alopecia are an exception to this criterion.
- Received prior radiotherapy within 2 weeks of the first dose of cyclophosphamide. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1- week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-central nervous system (CNS) disease.
- Carcinomatous meningitis; and/or active CNS metastases, unless metastases are treated and stable and the subject does not require systemic steroids.
- Known history of human immunodeficiency virus (HIV), known active hepatitis B virus (HBV; e.g., hepatitis B surface antigen [HBsAg] reactive), or hepatitis C virus (HCV; e.g., HCV ribonucleic acid [RNA] is detected)
- Prior treatment with HPV T cells
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Allogeneic bone marrow transplant
non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
|
Standard dosing for bone marrow graft (target dose of 4 x 10^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).
|
Experimental: CD8-depleted donor lymphocyte infusion (DLI) per dose escalation scheme
CD8-depleted donor lymphocyte infusion per dose escalation scheme from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.
|
Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10^6 CD4+ cells/kg; 2) 5 x 10^6 CD4+ cells/kg; or 3) 10^7 CD4+ cells/kg of recipient ideal body weight.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time Frame: 12 months
|
Determine the safety of the two interventions in patients with recurrent or metastatic HPV16-associated cancer.
Safety will be monitored for every patient and we will document and grade every adverse event using the NCI CTCAE version 5.0.
|
12 months
|
Maximum Tolerated Dose (MTD) of Allogeneic CD4+ T cell Infusion
Time Frame: 12 months
|
Determine the maximum tolerated dose (in CD4+ cells/kg) of allogeneic CD4+ T cells infused after cyclophosphamide in patients with recurrent or metastatic HPV16-associated cancer.
We will use three dose levels of allogeneic CD4+ T cells: 1) 10^6 CD4+ cells/kg; 2) 5 x 10^6 CD4+ cells/kg; 3) 10^7 CD4+ cells/kg of recipient ideal body weight.
We will implement a Bayesian optimal interval design to find the MTD with an observation period of 42 days for treatment-related toxicities.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of toxicities as assessed by the NCI CTCAE version 5.0
Time Frame: 12 months
|
Count the toxicities of allogeneic BMT and HPV-specific CD4+ T cells in patients with recurrent or metastatic HPV16-associated cancer.
Toxicities of treatment will be formally assessed and scored using the Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.
|
12 months
|
Progression-free survival (PFS) of allogeneic CD4+ T cell Infusion and allogeneic BMT
Time Frame: 12 months
|
PFS is defined as the date from transplantation to the date of relapse/progression, death from any cause or last follow-up, whichever comes first.
Kaplan-Meier curve will be generated and PFS will be estimated along with 95% confidence intervals.
|
12 months
|
Overall survival (OS) of allogeneic CD4+ T cell Infusion and allogeneic BMT
Time Frame: 12 months
|
OS is defined as the date from infusion or transplantation to the date of death from any cause or last follow-up.
A Kaplan-Meier curve will be generated along with 95% confidence intervals.
|
12 months
|
Overall Response of allogeneic CD4+ T cell Infusion and allogeneic BMT
Time Frame: Up to 12 months
|
Response will be defined as per the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and will be evaluated at 2, 6 and 12 months after transplantation or infusion.
|
Up to 12 months
|
Incidence of acute graft versus host disease (GVHD)
Time Frame: 12 months
|
Each patient will be monitored for acute GVHD and we will grade acute GVHD using the consensus conference clinical grading of acute GVHD.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Tanguy Seiwert, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 18, 2023
Primary Completion (Estimated)
October 1, 2025
Study Completion (Estimated)
October 1, 2025
Study Registration Dates
First Submitted
January 14, 2021
First Submitted That Met QC Criteria
January 14, 2021
First Posted (Actual)
January 19, 2021
Study Record Updates
Last Update Posted (Estimated)
November 3, 2023
Last Update Submitted That Met QC Criteria
November 1, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- J21112
- IRB00244082 (Other Identifier: JHM IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HPV 16+ Recurrent or Metastatic Cancer
-
Gilead SciencesTerminatedHuman Papillomavirus (HPV) 16+ Relapsed/Refractory CancerUnited States
-
Lee's Pharmaceutical LimitedUnknownCervical HPV-16 and / or HPV-18 InfectionChina
-
Memorial Sloan Kettering Cancer CenterCompletedHuman Papillomavirus (HPV)-Related Malignancies | Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related MalignanciesUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...WithdrawnRecurrent Human Papillomavirus Type 16 Associated CancerUnited States
-
National Cancer Institute (NCI)WithdrawnMetastatic HPV-16 Positive Squamous Cell Anal CancerUnited States
-
GenticelPPDTerminatedHPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSILUnited States
-
PharmaMatrix Holdings LtdUniversity of AlbertaRecruitingCancer: Recurrent and/or Metastatic Solid TumoursCanada
-
Memorial Sloan Kettering Cancer CenterCompletedMetastatic or Recurrent Lesions in the Spine | Metastatic or Recurrent Lesions in the PelvisUnited States
-
Dana-Farber Cancer InstituteActive, not recruitingRecurrent Head and Neck Carcinoma | Head and Neck Cancer Metastatic | Head or Neck CancerUnited States
-
AmgenCompletedRecurrent and/or Metastatic Head and Neck Cancer
Clinical Trials on Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16
-
Columbia UniversityActive, not recruitingSickle Cell Disease | Beta ThalassemiaUnited States
-
Massachusetts General HospitalCompletedMultiple Myeloma | End Stage Renal DiseaseUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...CompletedSevere Combined Immunodeficiency | Adenosine Deaminase Deficiency | Immune System Disorder | Autosomal Recessive Disorder | Purine-Nucleoside Phosphorylase Deficiency | Severe Combined Immunodeficiency With Absence of T and B Cells | X-Linked Severe Combined ImmunodeficiencyUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Fibrolamellar Cancer FoundationWithdrawnHepatocellular Carcinoma | Fibrolamellar Hepatocellular Carcinoma | Hepatocellular Carcinoma (Fibrolamellar Variant)United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...TerminatedGenetic Disorder | Severe Aplastic Anemia | Immunodeficiency SyndromeUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...CompletedPreviously Treated Myelodysplastic Syndrome | Fanconi Anemia | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia in RemissionUnited States, Brazil
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.Completed